Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clearside Biomedical, Inc.CLSD · Entity 82875 | Chief Medical Officer | January 20, 2023 | January 20, 2023 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Chief Medical Officer | February 05, 2024 | February 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clearside Biomedical, Inc.
Report date January 20, 2023 · Filed January 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 291,890 |
Reported balance
After 2023-01-20 transaction · row 1
1 source rowRow 1 · 2023-01-20 · Sale · Disposed 13,700 · Balance 291,890 F1: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Viridian Therapeutics, Inc.\DE
Report date February 05, 2024 · Filed February 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.70 · Expires 2034-02-05 | Direct | 50,000 |
Reported balance
After 2024-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-05 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests in 48 equal monthly installments, subject to the Reporting Person's continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 48 equal monthly installments, subject to the Reporting Person's continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2024 Filed Feb 7, 2024 16:01 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $18.70 | $0.00 |
DisclosureSEC source: 0000950170-24-012167 · ownership.xml · derivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-02-05 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 20, 2023 Filed Jan 20, 2023 16:32 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 13,700 | $1.47 | $20,139.00 |
DisclosureSEC source: 0001209191-23-004278 · doc4.xml · nonDerivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,890 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 16:39 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 2,170 | $1.62 | $3,515.40 |
DisclosureSEC source: 0001209191-23-002993 · doc4.xml · nonDerivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,590 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.6115 to $1.621 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 16:27 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantEmployee Stock Option (right to buy) · Derivative | 187,500 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001209191-23-002341 · doc4.xml · derivative · entry 3 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2033-01-04 F2 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 4, 2024 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date. Read SEC document |
| December 31, 2022 Filed Jan 6, 2023 16:27 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantCommon Stock | 5,000 | $0.95 | $4,750.00 |
DisclosureSEC source: 0001209191-23-002341 · doc4.xml · nonDerivative · entry 2 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,760 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2022 Filed Jan 6, 2023 16:27 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantCommon Stock | 5,000 | $1.25 | $6,250.00 |
DisclosureSEC source: 0001209191-23-002341 · doc4.xml · nonDerivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,760 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 19:06 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 9,050 | $2.13 | $19,276.50 |
DisclosureSEC source: 0001209191-22-004193 · doc4.xml · nonDerivative · entry 2 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,260 F2 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Includes 5,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 19:06 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (Right to Buy) · Derivative | 131,250 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-22-004193 · doc4.xml · derivative · entry 3 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2032-01-18 F4 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 19:06 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004193 · doc4.xml · nonDerivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,310 F1 · shares: These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2023, January 18, 2024, January 18, 2025 and January 18, 2026, subject to the Reporting Person's continuous service as of each such vesting date. Read SEC document |
| January 18, 2022 Filed Jan 28, 2022 16:53 UTC Amendment | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (Right to Buy) · Derivative | 138,750 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-22-005440 · doc4a.xml · derivative · entry 2 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,750 Underlying: Common Stock · 138,750 shares Expires 2032-01-18 F2 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date. Read SEC document |
| January 18, 2022 Filed Jan 28, 2022 16:53 UTC Amendment | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantCommon Stock | 46,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005440 · doc4a.xml · nonDerivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,810 F1 · shares: These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2023, January 18, 2024, January 18, 2025 and January 18, 2026, subject to the Reporting Person's continuous service as of each such vesting date. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 17:17 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 2,560 | $6.40 | $16,384.00 |
DisclosureSEC source: 0001209191-21-057461 · doc4.xml · nonDerivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,560 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Includes 4,998 shares acquired under the Issuer's employee stock purchase plan on June 30, 2021. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 19:33 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-017360 · doc4.xml · derivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-10-24 F1 · derivative.exercise_date: On October 24, 2018, the reporting person was granted an option to purchase 40,000 that vests in full based on the satisfaction of certain performance criteria. The performance criteria were met on March 1, 2021, resulting in the vesting of the option full. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 18:17 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (Right to Buy) · Derivative | 209,375 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001209191-21-004473 · doc4.xml · derivative · entry 2 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,375 Underlying: Common Stock · 209,375 shares Expires 2031-01-18 F3 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 18, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 18:17 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantCommon Stock | 103,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004473 · doc4.xml · nonDerivative · entry 1 Ciulla Thomas · CIK 0001815426 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,122 F1 · shares: These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2022, January 18, 2023, January 18, 2024 and January 18, 2025, subject to the Reporting Person's continuous service as of each such vesting date, and subject to accelerated vesting in specified circumstances. F2 · balance_after: Includes 4,997 shares acquired under the Issuer's employee stock purchase plan on December 31, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.